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High-level expression of Rad51, a key factor in homologous recombination, has been observed in a variety of human malignancies.
This study was aimed to evaluate Rad51 expression to serve as prognostic marker in non-small-cell lung cancer (NSCLC). A total of
383 non-small-cell lung tumours were analysed immunohistochemically on NSCLC tissue microarrays. High-level Rad51 expression
was observed in 29.4% (100 out of 340) of cases. Patients whose tumours displayed high-level Rad51 expression showed a
significantly shorter median survival time of 19 vs 68 months (Po0.0001, log-rank test). Similarly T status, N status, M status, clinical
stage and histological tumour grade were significant prognostic markers in univariate Cox survival analysis. Importantly, Rad51
expression (Po0.0001) together with tumour differentiation (Po0.009), clinical stage (P¼0.004) and N status (P¼0.0001) proved
to be independent prognostic parameters in multivariate analysis. Rad51 expression predicted the outcome of squamous cell cancer
as well as adenocarcinoma of the lung. Our results suggest that Rad51 expression provides additional prognostic information for
surgically treated NSCLC patients. We hypothesise that the decreased survival of NSCLC patients with high-level expression of
Rad51 is related to an enhanced propensity of tumour cells for survival, antiapoptosis and chemo-/radioresistance.
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Lung cancer continues to be the most frequent cancer with
approximately one million people worldwide dying of this disease
each year (Carney, 2002). Non-small-cell lung cancer (NSCLC),
which accounts for approximately 80% of all lung cancers, is
conceptualised as a group of heterogeneous clinical entities that
share a common cellular origin but have different clinical
behaviours, and hence, different prognoses. Although surgery is
the best therapeutic modality for patients with early stages of
NSCLC, patients with the same clinical stage of NSCLC display
considerable variability in recurrence and survival. Even after
radical surgery, a significant proportion of patients may suffer
from regional or distant recurrence (Buccheri and Ferrigno, 1994).
Therefore, there is an urgent need for new parameters that can
distinguish between patients with unfavourable prognosis and
others with better prognosis. If individuals with poor prognosis
could be identified at the time of surgery, their survival might be
prolonged by more effective adjuvant therapy.
Rad51, one of the key factors of DNA repair by homologous
recombination, has been shown to have antiapoptotic activity in
tumour cells (Henning and Stuerzbecher, 2003). A large body of
evidence indicates that Rad51 expression is associated with
carcinogenesis. Elevated recombination frequency along with
high-level expression of Rad51 was found in immortal human cell
lines compared to mortal cells (Xia et al, 1997). Elevated
expression of Rad51 enhances radioresistance of human tumour
cells (Vispe ´ et al, 1998; Yanagisawa et al, 1998). Overexpression of
Rad51 protein in tumour cells renders them resistant against
cytotoxic drugs like Cisplatin. Importantly, Ohnishi et al (1998)
found that treatment of monolayer cultures of tumour cells with
Rad51-specific antisense oligonucleotides renders those cells
radiosensitive. Rad51 protein is highly expressed in tumour cell
nuclei of several solid carcinomas (Maacke et al, 2000a). Rad51
protein interacts with a variety of tumour suppressor proteins
including p53 (Stuerzbecher et al, 1996), BRCA1 (Scully et al, 1997)
and BRCA2 (Sharan et al, 1997). Furthermore, Rad51 over-
expression correlates with histological grading of the tumour in
invasive ductal mammary carcinoma (Maacke et al, 2000b). Many
reports demonstrate that Rad51 is not only involved in the
progress of carcinogenesis but might also be highly significant in
clinical practice (Henning and Stuerzbecher, 2003).
Up to now, there is no report concerning expression pattern of
Rad51 in NSCLC and its clinical implication. Therefore, we used
tissue microarrays containing resected specimens of 383 NSCLC
patients for large-scale investigation of the prognostic value of
Rad51 expression in NSCLC.
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Patients and clinical samples
We used primary tumour tissue samples from patients diagnosed
with NSCLC pathological stage I–IV at the Lung Cancer Research
Institute & Cancer Center of Guangdong province, P.R. China
between January 1994 and December 1997. All patients were
consecutive Chinese patients with NSCLC and underwent surgical
treatment at the Department of Surgery of this institute. The study
protocol was approved by the Ethical Committee of Guangdong
Provincial People’s Hospital, Guangdong province; P R. China
and the Ethical Committee of University of Luebeck, Germany
(file 03–153). Excluding criteria were as follows: (1) patients who
had undergone chemotherapy or radiotherapy prior to surgery;
(2) patients who died within 3 months after surgery; (3) patients
whose cause of death remained unknown.
Totally, 383 patients and their corresponding resected tumour
specimens were recruited in this study. These patients had a
median follow-up of 34 months (range from 4 to 106 months). The
last follow-up was carried out in January of 2003. All detailed
information about demography, clinical manifestation and histo-
pathology of the patients was collected retrospectively. In many
cases of morphologically anaplastic large-cell carcinoma, assignment
to squamous cell carcinoma (SCC) or adenocarcinoma (ADC) was
verified by immunohistochemical demonstration of the cytokeratin
profile.
All surgically resected tumour specimens and control specimens
were fixed with 10% formalin and embedded in paraffin and
obtained from the archives of our institute. The tumours were
staged according to the International Union against Cancer’s
tumour-node-metastasis (TNM) classification (Mountain, 1997)
and histologically subtyped and graded according to the World
Health Organization guidelines (Sobin, 1982). All tumours and
control tissues were reviewed by two pathologists (Dan Xie,
Xin-yuan Guan).
Microarray construction
Construction of NSCLC tissue microarray was as follows. Three
most representative samples from each lung cancer case were
adopted for the TMA construction. The individual donor tissue
block and the corresponding histological haematoxylin–eosin-
stained slides were overlaid for tissue TMA sampling. A TMA
instrument (Beecher Instruments, Silver Spring, MD, USA) was
used to create holes in a recipient paraffin block in order to obtain
cylindrical core tissue biopsy samples with a diameter of 0.6mm
and to transfer these biopsy samples to the recipient block at
defined array positions. Hence, three TMAs slides include a total
of 1149 (383 3) samples. Multiple sections (5mm thick) were cut
from the TMA block and mounted on microscope slides.
Immunohistochemistry
Immunohistochemistry studies were performed using the standard
avidin–biotin complex (ABC) method. In brief, TMA sections
were deparaffinated and rehydrated. For antigen retrieval, TMA
slides were immersed in antigen retrieval solution (10mM citrate
acid, pH 6) and boiled for 15min in a pressure cooker.
Endogenous peroxidase activity was blocked by incubation in
3.5% hydrogen peroxide in PBS for 15min. After permeabilising
the cells with Triton-X 100 for 5min, specimens were blocked
in horse serum and subsequently with avidin and biotin (Vector
Laboratories, Burlingame, CA, USA). The TMA slides were
incubated with monoclonal mouse anti-human Rad51 antibody
1G8 (1mgml
 1; 1:5000dilution) (Buchhop et al, 1996; Maacke
et al, 2000b) for 60min at 371C in a moist chamber. After washing
in PBS, the slides were then sequentially incubated with a
biotinylated horse anti-mouse antibody (Vector Laboratories) at
a concentration of 1:100 for 60min at 371C. The slides were then
incubated with ABC complexes (Vector Laboratories) and stained
using DAB (diaminobenzidine tetrahydrochloride; Vector Labora-
tories) as peroxidase substrate. Specimens were counterstained
using Meyer’s haematoxylin (Merck, Darmstadt, Germany). The
slides were dehydrated and placed on coverslips. Negative control
was performed by replacing the primary antibody with blocking
serum. Slides from specimens that scored positive in previous
experiments were used as positive controls.
Assessment of immunohistochemistry
The immunostaining of TMA slides were assessed by two
pathologists (Dan Xie, Xin-yuan Guan) without being aware of
the clinical, pathological and follow-up data. The concept of
positive-cell index (PCI) (positive-stained cell index), which means
the proportion of positively stained tumour cells, was adapted for
the analyses in this study. At least 200 tumour cells were counted
to calculate the PCI in each specimen on TMA.
Since this study was focused on the prognostic role of molecular
tumour markers, an optimal cutoff point of marker index was
determined that allowed best separation of patients into those with
favourable and those with unfavourable clinical features and
prognosis. For this procedure, the corresponding P-values for all
candidates of cutoff points (numerical percentage values) were
calculated (Kronqvist et al, 1998) and the cutoff point representing
the highest statistical significance (i.e. the lowest P-value) was
regarded as the optimal threshold to separate prognostically
different groups. Using this method, a PCI of 10% was identified as
the optimal cutoff. Cases whose IHC scores were p10% were
called ‘low-level expressors’, whereas those with IHC scores 410%
were defined as ‘high-level expressors’.
Statistical analysis
All statistical analyses were performed using the SPSS 10.0.
statistical software package (SPSS Inc., Chicago, IL, USA).
Correlations between Rad51 expression and given categorised
parameters were evaluated using the nonparametric Mann–
Whitney U-test (for two categories) or Kruskal–Wallis test (for
multiple categories). Kaplan–Meier curves were plotted from
overall survival data, and the log-rank test was used for analysis of
differences between patients with different level of Rad51
expression.
Patients, who were still alive or lost to follow-up or died of other
causes than lung cancer recurrence or metastasis before January
2003, were treated as censored data in the survival analyses.
Multivariate survival analysis was performed using the Cox
Proportional Regression Hazard Model. For multivariate analysis,
all variables that proved to be significant in the univariate analysis
were selected in a stepwise fashion (forward selection of
covariates) to evaluate the predictive power of each variable
independently of the others. A P-value of 0.1 was adopted as the
limit for entering and removing covariates. The relative risks (RR)
and the associated 95% confidence intervals were calculated for
the prognostic factors that contributed significantly to the model.
For all analyses, statistical significance was assumed at a P-level of
o0.05.
RESULTS
Clinicopathologic variables and clinical outcome
A total of 383 patients suffering from NSCLC were included in this
study. Demographic, clinical and histopathological data (including
age, sex, histology, TNM stage, surgical procedure, tumour grade
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sand primary tumour site) were collected retrospectively. Data on
smoking history were missing for the majority of patients.
The median age of the patients was 59 years (range, 22–94
years) at the time of diagnosis, 71.3% of the patients were male. In
the majority of cases, lobectomy was performed (301 of 383
patients); 54 patients underwent pneumonectomy; 28 patients
received conservative lung resection. Complete resection was done
for 343 patients, incomplete resection for 40 patients. Incomplete
resection means either macroscopic evidence of the tumour or
metastatic lymph nodes left behind, microscopic evidence of the
tumour on the resected stump or clinical evidence of a distant
metastasis.
Histopathological examination of resected tumours revealed
that ADC was the dominant histological group (192 cases), 132
cases were SCCs, 44 adenoSCCs, two anaplastic large-cell
carcinomas, five lung sarcomas and eight were other less common
malignant neoplasms including carcinoid tumour, adenoid cystic
carcinoma and mucoepidermoid carcinoma.
Postoperative staging evaluation demonstrated that 110 had
stage I disease, 91 had stage II disease, 124 had stage IIIA disease,
37 had stage IIIB disease, and 21 had stage IV disease. In all, 21 had
T1 disease, 194 had T2 disease, 130 had T3 disease and 38 had T4
disease. A total of 171 had N0 disease, 78 had N1 disease, 126 had
N2 disease and eight had N3 disease. In total, 209 tumours were
located in the upper lobe, 31 were in the middle lobe, 130 were in
the lower lobe and 13 were mixed or hard to be distinguished.
Univariate analyses of the demographic and clinical variables
revealed that tumour state (T status), lymph node status (N status),
metastasis status (M status), clinical stage and tumour grade all
had prognostic significance with regard to overall survival. The
results are presented in Table 1.
Pattern of Rad51 expression in NSCLC and correlation to
clinicopathological parameters
Immunochemical staining revealed 340 informative cases that
could be assessed and scored under the light microscope. Positive
tumour cells generally showed a nuclear staining pattern in
NSCLC. There were much more positive nuclear staining cells in
tumour tissue compared to normal lung tissue. This pattern
allowed the classification of Rad51 expression by PCI. The
expression status of Rad51 was classified into two groups: (1)
low-level expression: PCIp10%; (2) high-level expression: PCI
410%.
Figure 1 illustrates representative examples of the different levels
of Rad51 staining in SCC and ADC of NSCLC. Figure 2 gives the
high order magnification picture of a SCC specimen exhibiting
high-level expression of Rad51.
Rad51 expression status was correlated with clinicopathological
features. The relationship between Rad51 expression and clinico-
pathological features in NSCLC is shown in Table 2. Of 340 (29.4%)
NSCLC cases, 100 showed high-level expression of Rad51, inclu-
ding 32 of 117 (27.4%) SCC and 53 of 169 (31.4%) ADC.
We found no significant correlation between Rad51 expression
and age, sex, tumour status (T status), lymph node status (N status),
metastasis status (M status), clinical stage, tumour cell type and
differentiation.
Relationship between Rad51 expression and clinical
outcome in NSCLC: univariate survival analysis
The results of Rad51 expression were analysed with regard to
overall survival time of the patients. Univariate survival analysis
(log-rank test) demonstrated significant association between
overall survival and the status of Rad51 (Po0.0001). Patients with
high-level expression of Rad51 had a poorer prognosis than did
those with low-level expression. Expression of Rad51 had an
important impact on lung cancer survival regardless of the
histological cell type. Patients with high-level expression of
Rad51 had a poorer prognostic outcome regardless of SCC
(Po0.0001) and ADC (P¼0.0423) of NSCLC. Additionally,
survival analysis was performed with regard to Rad51 expression
in subsets of patients with different clinical stages. The results
demonstrated that high-level expression was a prognostic factor in
stage I–III NSCLC patients (P-values: 0.0072, 0.0041 and 0.0016,
respectively). However, Rad51 expression could not differentiate
the outcome of stage IV NSCLC patients (P¼0.6229).
Table 3 presents the results of univariate analysis with regard to
Rad51 expression and overall survival of NSCLC. Figure 3 shows
Kaplan–Meier survival curves in relation to Rad51 expression in
subsets of patients with SCC and ADC of the lung. Figure 4 shows
Kaplan–Meier survival curves in relation to Rad51 expression in
subsets of different clinical stage NSCLC patients.
Table 1 Predictive variables for prognosis of 383 NSCLC patients by
univariate analysis (log-rank test)
Variables
Patients
(cases)
Mean
survival
(months)
Median
survival
(months)
5-year
survival
(%) P-value
Age
p59 years (median) 184 55 45 44 0.974
459 years 199 55 37 44
Sex
Male 273 55 39 45 0.865
Female 110 55 34 42
T status
1 21 84 n.r.
a 75 o0.001
2 194 61 49 47
3 130 50 31 41
43 8 2 9 1 7 2 1
N status
0 171 72 n.r.
a 62 o0.001
17 8 5 7 4 5 4 8
2 126 29 22 16
3 8 21 16 0
M status
0 362 56 42 45 0.041
12 1 3 7 2 5 2 0
Stage
I 110 79 n.r.
a 67 o0.001
II 91 59 62 54
III 161 36 22 23
IV 21 37 25 19
Histology
Squamous carcinoma 132 60 59 49 0.448
Adenocarcinoma 192 52 34 41
Adenosquamous 44 47 33 41
Others
b 15 57 46 47
Tumour grade
G1 70 68 78 59 o0.001
G2 183 54 37 40
G3 130 36 15 28
Surgical procedure
Lobectomy 301 57 45 46 0.222
Pneumonectomy 54 45 31 40
Conservative
resection
c
28 37 32 26
an.r.¼not reached.
bOthers include anaplastic large-cell carcinoma, sarcoma, adenoid
cystic carcinoma, mucoepidermoid carcinoma and carcinoid tumour.
cConservative
resections include segmentectomy and wedge resection.
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Cox regression analysis
Since variables found to have prognostic influence by univariate
analysis may covariate, all statistically significant variables from
the univariate analysis were included in the multivariate regression
analysis to identify independent prognostic factors. The data
obtained are presented in Table 4. Rad51 expression proved to be
an independent prognostic factor (Po0.001) as did lymph node
metastasis (P¼0.009), clinical stage (P¼0.004) and tumour grade
(Po0.001).
DISCUSSION
At present, the TNM staging system is considered the most
accurate predictor for NSCLC (Grondin and Liptay, 2002).
However, the anatomic TNM staging system, based on histo-
pathology and extent of disease at presentation, has reached its
limit in providing critical information that may influence the
strategy of treatment. Patients with the same pathological and
clinical stage of NSCLC display considerable variability in
recurrence and survival (Buccheri and Ferrigno, 1994). Therefore,
a substantial amount of research on the biology of NSCLC has
focused on evaluating the potential of new molecular markers
present in tumour cells to serve as prognostic factors or possible
targets for therapy. Although a variety of molecular markers have
been implicated in the prognosis of NSCLC, conflicting results
were widely reported in the literature (Brundage et al, 2002). Thus,
further investigations are required to develop appropriate markers
Figure 1 Representative examples of Rad51 protein expression in
NSCLC. (A) Low-level expression of Rad51 in SCC (PCIo10%); (B) high-
level expression of SCC (PCI¼60%); (C) low-level expression of ADC
(PCIo10%); (D) high-level expression of ADC (PCI¼80%); magnification
1 10; detection of Rad51 protein by immunohistochemistry using the
monoclonal anti-Rad51 antibody 1G8 (Buchhop et al, 1996); counter-
staining with Hemalum; red arrows mark tumour cells expressing high levels
of Rad51.
Figure 2 Representative example of high-level expression of Rad51 in
lung squamous cell lung carcinoma at magnification 10 40. Detection of
Rad51 protein by immunohistochemistry using the monoclonal anti-Rad51
antibody 1G8 (Buchhop et al, 1996); counterstaining with Hemalum; red
arrows mark tumour cells expressing high levels of Rad51.
Table 2 Relation between Rad51 expression and clinicopathological
parameters in 235 cases of NSCL
Rad51 (cases and percentage)
Parameters  
a +
b P-value
Total 240 (70.6%) 100 (29.4%)
Age
p59 years 119 (73.5%) 43 (26.5%) 0.269
459 years 121 (68.0%) 57 (32.0%)
Sex
Male 171 (70.1%) 73 (29.9%) 0.744
Female 69 (71.9%) 27 (28.1%)
T status
1 14 (66.7%) 7 (33.3%) 0.771
2 124 (72.9%) 46 (27.1%)
3 77 (67.5%) 37 (32.5%)
4 25 (71.4%) 10 (28.6%)
N status
0 105 (70.5%) 44 (29.5%) 0.513
1 54 (77.1%) 16 (22.9%)
2 76 (67.3%) 37 (37.2%)
3 5 (62.5%) 3 (37.5%)
M status
0 226 (70.8%) 93 (29.2%) 0.684
1 14 (66.7%) 7 (33.3%)
Stage
I 71 (74.7%) 24 (25.3%) 0.756
II 56 (70.0%) 24 (30.0%)
III 99 (68.8%) 45 (31.3%)
IV 14 (66.7%) 7 (33.3%)
Histology
SCC
c 85 (72.6%) 32 (27.4%) 0.891
ADC
d 116 (68.6%) 53 (31.4%)
ADSCC
e 29 (72.5%) 11 (27.5%)
Others
f 10 (71.4%) 4 (28.6%)
Tumour grade
G1 41 (66.1%) 21 (33.9%) 0.535
G2 109 (66.7%) 52 (33.3%)
G3 90 (76.9%) 27 (23.1%)
a ¼low-level expression of Rad51.
b+¼high-level expression of Rad51.
cSCC¼
squamous cell carcinoma.
dADC¼adenocarcinoma.
eADSCC¼adenosquamous
carcinoma.
fothers include anaplastic large-cell carcinoma, sarcoma, adenoid cystic
carcinoma, mucoepidermoid carcinoma and carcinoid tumour.
Rad51 as prognostic marker in non-small-cell lung cancer
G-B Qiao et al
140
British Journal of Cancer (2005) 93(1), 137–143 & 2005 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sor panels of molecular markers, as well as good quality control in
detection of the disease.
Rad51 is the key enzyme for homologous recombination, an
evolutionarily conserved mechanism for the repair of DNA damage
and the generation of genetic diversity (Henning and Stuerzbecher,
2003). In order to investigate the role of Rad51 in NSCLC, we
examined immunohistochemically Rad51 expression in NSCLC
tissues using high throughput tissue microarrays. Consistent with
studies in several other tumour entities, including breast cancer
and pancreatic ADC (Maacke et al, 2000a,b; Han et al, 2002;
Raderschall et al, 2002), our results demonstrate that Rad51 is
overexpressed in tumour cell nuclei in NSCLC compared to normal
tissues. In all, 29.4% of NSCLC showed high-level expression of
Rad51. These findings, together with results from previous studies,
suggest a role for abnormal expression of the mammalian Rad51
recombination protein in the multistep process of tumorigenesis.
Most importantly, this is the first study to evaluate the
prognostic value of Rad51 in NSCLC patients. The data presented
revealed that the median survival time and 5-year survival rate in
patients with high-level expression of Rad51 appear shorter and
lower than that of patients with low Rad51 expression. The median
survival time of patients with Rad51 high-level expression was 19
months, compared to 68 months for patients with low-level
expression. The 5-year survival rate of patients with Rad51 high-
level expression was 24.9%, but for patients with low-level
expression of Rad51 it was 50.3%. Additionally, stratified survival
analysis by histological tumour cell type demonstrated that Rad51
expression was closely related to the survival of both lung SCC and
lung ADC. Furthermore, Rad51 expression was an independent
factor in NSCLC patients. Therefore, our findings demonstrate
that Rad51 expression has the potential to predict the outcome
of NSCLC patients. The assessment of Rad51 expression may,
therefore, be used as an additional tool in identifying those
patients at risk of tumour recurrence and progression, and it may
be a helpful criterion to optimise individual therapy management.
These findings raise the question of the pathological role of
Rad51 in the development of NSCLC. Elimination of Rad51 in mice
leads to sensitivity towards ionising radiation and early embryonic
lethality (Tsuzuki et al, 1996). Conditional inhibition of Rad51
transcription in untreated chicken DT40 cells results in G2/M
arrest with high levels of chromosome-type breaks (Sonoda et al,
1998). These data suggest that Rad51 might be essential for
survival in higher eukaryotic cells, presumably due to its role in
repairing DNA double-strand breaks arising during DNA replica-
tion. Moreover, elevated expression of Rad51 and/or homologous
recombination activity in immortal human cells may contribute to
survival and/or increased genetic instability. Enhanced expression
of Rad51 protein in tumour cells is associated with high DNA
repair capacity, elevated recombination rates and increased
resistance against radio- and chemotherapy (Henning and
Stuerzbecher, 2003). Our present results of NSCLC and data from
Table 3 Prognostic value of Rad51 in NSCLC patients by univariate
analysis (log-rank test)
Rad51 expression
Patients
(cases)
Mean
survival
(months)
Median
survival
(months)
5-year
survival
(%) P-value
Total
Low-level expression 240 61 68 50.3 o0.0001
High-level expression 100 38 19 24.9
Cell type
Squamous carcinoma
Low-level expression 85 68 78 61.3 o0.0001
High-level expression 32 28 17 18.8
Adenocarcinoma
Low-level expression 116 54 37 44.8 0.0423
High-level expression 53 42 24 28.3
Clinical stage
Stage I
Low-level expression 71 82 n.r.
a 75.7 0.0072
High-level expression 24 49 48 40.9
Stage II
Low-level expression 56 63 n.r.
a 60.8 0.0041
High-level expression 24 39 17 37.5
Stage III
Low-level expression 99 41 26 30.0 0.0016
High-level expression 45 21 17 7.4
Stage IV
Low-level expression 14 32 26 26.8 0.6229
High-level expression 7 35 7 28.6
an.r.¼not reached.
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Figure 3 Kaplan–Meier survival analysis according to Rad51 expression
in subsets of patients with SCC and ADC of the lung (log-rank test). SCC,
probability of survival of squamous cell carcinoma of NSCLC patients: low-
level expression (solid line), n¼85; high-level expression (dashed line),
n¼32. ADC, probability of survival of adenocarcinoma of NSCLC patients:
low-level expression (solid line), n¼116; high-level expression (dashed
line), n¼53.
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spapillary bladder carcinoma (Krueger et al, unpublished), as well
as breast cancer (Maacke et al, 2000b) and pancreatic cancer
(Maacke et al, 2000a; Han et al, 2002) strongly suggest that high-
level Rad51 expression might be a permissive event for tumour
progression, probably because it helps to keep DNA damage at a
tolerable level for cell survival and at the same time enhancing
genetic instability. Unfortunately, no adequate information on
adjuvant treatment of the patients was available in this retro-
spective series. Therefore, no conclusions can be drawn about a
potential role of Rad51 expression as predictor of response to
therapy. It is however tempting to speculate that Rad51 expression
might also predict therapy response of the individual NSCLC
patient on the basis of in vitro data, indicating the involvement of
Rad51 activity in mechanisms of therapy resistance after the
treatment of cells with DNA-damaging agents or irradiation
(Henning and Stuerzbecher, 2003).
In summary, the present study introduces Rad51 expression as
independent prognostic factor in NSCLC with elevated levels of
Rad51 protein in tumour cells predicting poor outcome of the
disease for the individual patient. Our findings have possible
therapeutic applications. Rad51 could serve as a prognostic marker
to improve tumour classification of NSCLC. More importantly,
downregulation of Rad51 protein by Rad51 RNAi technology or
Rad51-inhibitory drugs could be used to sensitise tumours to
radiation or chemotherapy.
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Figure 4 Kaplan–Meier survival analysis according to Rad51 expression in subsets of different clinical stage I–IV NSCLC patients (log-rank test): Stage I,
probability of survival of stage I NSCLC patients: low-level expression (solid line), n¼71; high-level expression (dashed line), n¼24. Stage II, probability of
survival of stage II NSCLC patients: low-level expression (solid line), n¼56; high-level expression (dashed line), n¼24. Stage III, probability of survival of
stage III NSCLC patients: low-level expression (solid line), n¼99; high-level expression (dashed line), n¼45. Stage IV, probability of survival of stage IV
NSCLC patients: low-level expression (solid line), n¼14; high-level expression (dashed line), n¼7.
Table 4 Multivariate analysis on overall survival (Cox regression model)
Factors Relative risk (RR) 95% CI P-value
N status
a 1.368 1.080–1.733 0.009
Stage
b 1.433 1.123–1.829 0.004
Differentiation
c 0.608 0.494–0.747 o0.001
Rad51
d 1.926 1.435–2.585 o0.001
aN3 vs N2 vs N1 vs N0.
bI vs II vs III vs IV.
cPoor vs moderate vs well.
dHigh-level
expression vs low-level expression.
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